Table 1 Characteristics of evaluable patientsa.

From: Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia

Characteristics

Pediatric (n = 17)

Adult (n = 30)

Total (n = 47)

Sex—no. (%)

   Female

8 (47.1)

16 (53.3)

24 (51.1)

   Male

9 (52.9)

14 (46.7)

23 (48.9)

Age at infusion—y

   

   Median

7.0

32.0

22.0

   Range

3–13

14–72

3–72

Previous chemotherapy—no. (%)

   ≥10

8 (47.1)

11 (36.7)

19 (40.4)

   <10

9 (52.9)

19 (63.3)

28 (59.6)

Previous allo-HSCT—no. (%)

   Yes

4 (23.5)

5 (16.7)

9 (19.1)

   No

13 (6.5)

25 (83.3)

38 (80.9)

Primary refractory disease—no. (%)

0

3 (10.0)

3 (6.4)

Relapse—no. (%)

   1 time

12 (70.6)

13 (43.3)

25 (53.2)

   ≥2 times

5 (29.4)

14 (46.7)

19 (40.4)

Percentage of blasts in bone marrow—no. (%)

   <5%

4 (23.5)

11 (36.7)

15 (31.9)

   ≥5% and <20%

2 (11.8)

4 (13.3)

6 (12.8)

   ≥20%

11 (64.7)

15 (50.0)

26 (55.3)

Cytogenetic factorsb—no. (%)

   No data

1 (5.9)

2 (6.7)

3 (6.4)

   Undetermined significance

2 (11.8)

3 (10.0)

5 (10.6)

   TEL/AML1

1 (5.9)

0

1 (2.1)

   Normal

4 (23.5)

6 (20.0)

10 (21.3)

   Ph+ or BCR/ABL1 with T315I mutation

0

4 (13.3)

4 (8.5)

   Ph+ or BCR/ABL1 without T315I mutation

2 (11.8)

5 (16.7)

7 (14.9)

   BCR/ABL like fusions

2 (11.8)

1 (3.3)

3 (6.4)

   MLL translocation

1 (5.9)

2 (6.7)

3 (6.4)

   E2A/PBX1

1 (5.9)

4 (13.3)

5 (10.6)

   HOX11

0

1 (3.3)

1 (2.1)

   Complex karyotype

3 (17.6)

2 (6.7)

5 (10.6)

Extramedullary diseases (EMDs) before infusionc—no. (%)

3 (17.6)

10 (33.3)

13 (27.7)

   CNS involvement (central nervous system involvement) only

0

6 (20.0)

6 (12.8)

   Testicle

1 (5.9)

1 (3.3)

2 (4.3)

   Breast

0

1 (3.3)

1 (2.1)

   CNS involvement and multi-site bone infiltration simultaneously

0

1 (3.3)

1 (2.1)

   Multi-site bone and soft-tissue infiltration simultaneously

2 (11.8)

1 (3.3)

3 (6.4)

Percentage of regulatory T cells in peripheral bloodd—no. (%)

   

   ≥Upper limits of normal value

10 (58.8)

18 (62.1)

28 (60.9)

   <Upper limits of normal value

7 (41.2)

11 (37.9)

18 (39.1)

Preconditioning chemotherapye—no. (%)

   FC

9 (52.9)

16 (53.3)

25 (53.2)

   VDCP

1 (5.9)

5 (16.7)

6 (12.8)

   Cy

7 (41.2)

7 (23.3)

14 (29.8)

   Not given

0

2 (6.7)

2 (4.3)

  1. aPercentages may not total 100 because of rounding.
  2. bPh+ means Philadelphia chromosome positive.
  3. cExtramedullary diseases (EMDs) were defined as CD19+ B lymphoblastic cells outside the bone marrow, detected by revealing abnormal masses in extramedullary sites. Imaging examinations, such as magnetic resonance imaging, computed tomography or positron-emission tomography, and cytological or pathological biopsy examinations were used to detect blast cells in these masses (Fig. 6). CNS involvement (central nervous system involvement) was defined as blast cells detected in cerebrospinal fluid (CSF sample with ≥5 leukocytes per cubic millimeter and <10 erythrocytes per cubic millimeter).
  4. dTregs data were not available for one patient.
  5. eFC (fludarabine 25 mg m−2 followed by cyclophosphamide 400 mg m−2 × 5 days) was used if a patient had normal white blood cell count and active bone marrow hyperplasia; VDCP (vincristine 1 mg m−2 + daunorubicin 60 mg m−2 + cyclophosphamide 600 mg m−2) × 1 day + prednisone 2 mg kg−1 × 7 days then followed by FC × 3 days, if a patient had higher tumor burden such as percentage of marrow blasts ≥50% or EMD positive; Cy (cyclophosphamide, 400 mg m−2 × 3 days), if a patient had leukopenia and hypoplastic marrow; not given, for two aged patients.
  6. Source data are provided as a Source Data file or available at https://doi.org/10.6084/m9.figshare.13136078.v1.
Back to article page